Literature DB >> 19031093

Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus.

Márcio Veronesi Fukuda1, Simone Chinwa Lo, Cláudia Salvini de Almeida, Samuel Katsuyuki Shinjo.   

Abstract

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with various clinical and serological manifestations. Previous studies have shown the association of SLE and anti-Ro antibody with a series of clinical manifestations. We investigated this association in Brazilian patients with SLE. Five hundred and nine consecutive patients who fulfilled the revised American College of Rheumatology criteria for the SLE were enrolled in the study from June to December 2007. All patients were from our Service of Rheumatology, School of Medicine, University of São Paulo, Brazil. Frequencies of a series of laboratorial and clinical manifestations were calculated. Anti-Ro antibody was associated to anti-La antibody, female, and cutaneous vasculitis. In multivariate analysis, patients with anti-Ro antibody has 1.63 (95% CI 1.07-2.50) more risk to develop cutaneous vasculitis than patients without this antibody. Our data have demonstrated that anti-Ro antibody is an independent useful serologic marker for cutaneous vasculitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031093     DOI: 10.1007/s10067-008-1043-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES.

Authors:  E L DUBOIS; D L TUFFANELLI
Journal:  JAMA       Date:  1964-10-12       Impact factor: 56.272

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.

Authors:  E L Alexander; F C Arnett; T T Provost; M B Stevens
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

Review 4.  Cutaneous lesions in systemic lupus erythematosus.

Authors:  R Watson
Journal:  Med Clin North Am       Date:  1989-09       Impact factor: 5.456

Review 5.  Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus.

Authors:  J B Harley; R H Scofield; M Reichlin
Journal:  Rheum Dis Clin North Am       Date:  1992-05       Impact factor: 2.670

6.  Cutaneous manifestations of systemic lupus erythematosus.

Authors:  J A Yell; J Mbuagbaw; S M Burge
Journal:  Br J Dermatol       Date:  1996-09       Impact factor: 9.302

7.  Systemic lupus erythematosus. A prospective analysis.

Authors:  R Grigor; J Edmonds; R Lewkonia; B Bresnihan; G R Hughes
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

8.  Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets.

Authors:  M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

9.  Detection of anti-Ro(SSA) antibodies by gel double diffusion and a 'sandwich' ELISA in systemic and subacute cutaneous lupus erythematosus and Sjögren's syndrome.

Authors:  T T Provost; L S Levin; R M Watson; M Mayo; H Ratrie
Journal:  J Autoimmun       Date:  1991-02       Impact factor: 7.094

10.  Cutaneous manifestations of primary Sjögren's syndrome: a reflection of vasculitis and association with anti-Ro(SSA) antibodies.

Authors:  E L Alexander; T T Provost
Journal:  J Invest Dermatol       Date:  1983-05       Impact factor: 8.551

View more
  12 in total

1.  Anti-Ro antibody and clinical manifestations: lessons from systemic lupus erythematosus in the elderly.

Authors:  Rui-Xue Leng; Wei-Zi Qin; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2010-06-12       Impact factor: 2.980

2.  Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice.

Authors:  Guo-Min Deng; Lena Liu; George C Tsokos
Journal:  Arthritis Rheum       Date:  2010-08

3.  Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon.

Authors:  Samuel Katsuyuki Shinjo; Eloísa Bonfá
Journal:  Clin Rheumatol       Date:  2010-03-28       Impact factor: 2.980

Review 4.  Connective Tissue Disorder-Associated Vasculitis.

Authors:  Aman Sharma; Aadhaar Dhooria; Ashish Aggarwal; Manish Rathi; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

5.  Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus.

Authors:  Ryusuke Yoshimi; Yoshiaki Ishigatsubo; Keiko Ozato
Journal:  Int J Rheumatol       Date:  2012-06-04

Review 6.  Cutaneous vasculitis: a rheumatologist perspective.

Authors:  Trinitario Pina; Ricardo Blanco; Miguel A González-Gay
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.919

7.  The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.

Authors:  Kristy Purnamawati; Jamie Ann-Hui Ong; Siddharth Deshpande; Warren Kok-Yong Tan; Nihar Masurkar; Jackson Kwee Low; Chester Lee Drum
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

Review 8.  Clinical and pathological roles of Ro/SSA autoantibody system.

Authors:  Ryusuke Yoshimi; Atsuhisa Ueda; Keiko Ozato; Yoshiaki Ishigatsubo
Journal:  Clin Dev Immunol       Date:  2012-12-06

Review 9.  Genetics and autoantibodies.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Fulvia Ceccarelli; Guido Valesini; Juan-Manuel Anaya; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 4.505

Review 10.  Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.

Authors:  Emanuele Cozzani; Massimo Drosera; Giulia Gasparini; Aurora Parodi
Journal:  Autoimmune Dis       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.